News

Supernus Pharmaceuticals Targets Advancement in CNS Treatments

Supernus Pharmaceuticals Targets Advancement in CNS Treatments

Supernus Pharmaceuticals Prepares for CNS Therapeutics Conference

ROCKVILLE, Md. — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a key player in the biopharmaceutical industry, specializes in developing innovative treatments for central nervous system (CNS) diseases. Recently, the company announced an important upcoming appearance at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference, where Jack A. Khattar, President and CEO, is scheduled to give a presentation on December 8, 2025, at 3:20 p.m. ET.

Engagement with Investors

Supernus Pharmaceuticals is keen to engage with interested investors during this conference. Those wishing to connect with company leadership are encouraged to reach out to the conference coordinator at Bank of America for potential meeting arrangements. Furthermore, a live audio webcast of the presentation will be available for participants who wish to follow along remotely. Please check the Supernus Pharmaceuticals Investor Relations website to access the presentation and other relevant materials.

Accessing the Live Webcast

The live audio webcast featuring Jack A. Khattar’s presentation will be available through the Supernus Pharmaceuticals Investor Relations portal. An archived version of this webcast will also be accessible for 60 days following the conclusion of the conference, ensuring that those who cannot attend live can still gain insight into the company’s latest developments.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is dedicated to the development and commercialization of products aimed at treating CNS diseases. Their extensive portfolio includes established treatments for various conditions, including attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease patients using levodopa-based therapies, hypomobility in Parkinsonian patients, postpartum depression, epilepsy, migraine, and chronic sialorrhea. Moreover, the company is actively advancing a range of novel product candidates targeting various CNS disorders.

Diverse Portfolio and Innovation

The commitment of Supernus Pharmaceuticals to innovation in neuroscience reflects in their comprehensive pipeline aimed at producing effective interventions for patients with CNS conditions. The company's research and development efforts are grounded in understanding patient needs and developing therapies that can improve their quality of life.

Continued Commitment to Excellence

Supernus Pharmaceuticals remains focused on pursuing excellence in the biopharmaceutical sector. Their commitment extends beyond product development; the company actively seeks to enhance its manufacturing capabilities, establish collaborations for research and development, and navigate the regulatory landscape efficiently. By doing so, they aim to ensure that groundbreaking treatments arrive in the hands of those who need them the most.

Stay Informed

For ongoing updates and further information on their product pipelines, clinical trials, and corporate strategies, follow Supernus Pharmaceuticals through their Investor Relations website. This transparency allows stakeholders and the public to stay informed about important developments and strategies intended to drive the company forward.

Frequently Asked Questions

What is the purpose of the upcoming conference?

The conference serves as a platform for Supernus Pharmaceuticals to present its advancements in CNS treatments and engage with investors and stakeholders.

How can investors connect with Supernus Pharmaceuticals during the event?

Investors can reach out to the Bank of America conference coordinator to schedule meetings with company management.

What types of conditions does Supernus Pharmaceuticals focus on?

They focus on various CNS diseases, including ADHD, Parkinson's disease, epilepsy, migraines, and more.

Will the presentation be accessible after the live event?

Yes, a replay of the presentation will be available on the Supernus Pharmaceuticals website for 60 days after the conference.

How does Supernus Pharmaceuticals support innovation?

Supernus fosters innovation through extensive research, collaboration, and an unwavering commitment to developing effective treatments for CNS disorders.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 5

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 2

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 5

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 6

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
USPS Honors 150 Years of the U.S. Coast Guard Academy

Updated Category News Views 7

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 10

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 5

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 4

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
SMPL Faces Legal Drama: What Investors Need to Know

Updated Category News Views 5

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 9

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading

Top 5 Most Recently Viewed Articles

Prenetics Posts Impressive Q2 Results, Eyes $100M ARR Goal

Updated Category News Views 135

Prenetics Shows Significant Growth in Q2 Financial Results Prenetics Global Limited (NASDAQ: PRE) has announced robust financial results for the second quarter of 2025, underscoring the company's rapid growth and its strategic focus in the health sciences sector. This announcement highlights a remarkable increase in revenue and significant advancements in their business...

Continue Reading
Alvotech Engages Investors at Barclays Global Healthcare Conference

Updated Category News Views 108

Engagement with Investors at Barclays Healthcare Conference Recently, Alvotech (NASDAQ: ALVO), a leading biotech company recognized for its dedication to developing biosimilar medicines, announced exciting participation in a prominent global healthcare event. This year's Barclays 27th Annual Global Healthcare Conference is set to take place in a city rich with innovation...

Continue Reading
The BANK of Greenland Raises 2024 Profit Expectations Significantly

Updated Category News Views 58

Positive Outlook for The BANK of Greenland in 2024 The BANK of Greenland has recently made a notable adjustment to its profit expectations for the upcoming year. This upward adjustment comes on the heels of a successful performance reported during the first nine months of the year. Revised Profit Forecast for 2024 Based on the bank's impressive results, the projected...

Continue Reading
Visa Inc. Investors Urged to Connect with Legal Team for Rights

Updated Category News Views 96

Important Legal Notice for Visa Inc. Shareholders In a significant update for shareholders of Visa Inc. (NYSE: V), it has come to light that there is an ongoing class action securities lawsuit. This development, informed by Levi & Korsinsky, LLP, alerts investors to protect their rights and seek possible compensation for losses sustained during a specified time frame....

Continue Reading
Dentistry's Elite Voices Spotlighted in New Issue

Updated Category News Views 8

A Platform for Dentistry's Finest This ain't your average glossy magazine dropping a cent or two on general healthcare gossip. What INFLUENCE élevé does, it spins a tale that dentists, investors, and the curious onlookers crave. We're talkin' about a broad swath of experts who've stitched their names into the fabric of modern dental practices. Why a Special Issue? The...

Continue Reading